Key regions: United Kingdom, Germany, France, South Korea, Italy
The COVID-19 Vaccines market in United Arab Emirates has seen significant growth in recent months.
Customer preferences: The United Arab Emirates has been actively working to vaccinate its population against COVID-19. The government has made it a priority to provide access to vaccines to all citizens and residents. As a result, there is a high demand for vaccines among the population. Many people are willing to pay for vaccines to ensure they are protected against the virus.
Trends in the market: The COVID-19 Vaccines market in United Arab Emirates has been growing rapidly due to the high demand for vaccines. The government has been working with pharmaceutical companies to ensure a steady supply of vaccines to the country. The Pfizer-BioNTech vaccine was the first to be approved in the country, followed by the Sinopharm vaccine. The government has also approved the use of the AstraZeneca vaccine. The vaccination drive has been successful, with a large percentage of the population receiving at least one dose of the vaccine.
Local special circumstances: The United Arab Emirates has a large expatriate population, with many people coming from countries with limited access to vaccines. The government has made it a priority to provide vaccines to all residents, regardless of their nationality. This has helped to ensure that everyone in the country is protected against the virus, which is essential for maintaining public health and safety.
Underlying macroeconomic factors: The United Arab Emirates has a strong economy, which has allowed the government to invest heavily in the vaccination drive. The government has also been working with pharmaceutical companies to ensure a steady supply of vaccines to the country. The success of the vaccination drive has helped to boost consumer confidence and support economic recovery. Overall, the COVID-19 Vaccines market in United Arab Emirates is expected to continue to grow as the government works to vaccinate the entire population.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
